Related Experiment Video

Updated: Dec 11, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.2K

Therapeutic Options for the Treatment of Coronavirus Disease (COVID-19)

Jessica Snawerdt1, Lauren Finoli, Derek N Bremmer

  • 1Department of Pharmacy (Drs Snawerdt, Finoli, and Bremmer), Division of Pulmonary Critical Care (Dr Cheema), and Division of Infectious Disease (Dr Bhanot) Allegheny General Hospital, Allegheny Health Network, Pittsburgh, Pennsylvania.

Critical Care Nursing Quarterly
|August 25, 2020
PubMed

Insights

The COVID-19 pandemic necessitates rapid identification of treatments. While SARS-CoV-2 genomic sequencing offers targets, no definitive therapies are proven yet, with supportive care being primary.

Area of Science:

  • Infectious Diseases
  • Virology
  • Pharmacology

Background:

  • The COVID-19 pandemic, caused by SARS-CoV-2, presents a critical challenge for developing effective treatments.
  • Rapid genomic sequencing of SARS-CoV-2 has identified numerous potential therapeutic targets.
  • Existing knowledge on COVID-19 treatments is rapidly evolving.

Purpose of the Study:

  • To review the current landscape of therapeutic options for COVID-19.
  • To highlight the challenges in identifying safe and effective treatments during the pandemic.
  • To discuss the role of repurposed and investigational agents.

Main Methods:

  • Review of current scientific literature and clinical trial data.
  • Analysis of genomic sequencing data for therapeutic target identification.
  • Assessment of the efficacy and safety of investigational agents for COVID-19.

Main Results:

  • No definitively proven effective therapies for COVID-19 are currently available.
  • Several repurposed and investigational agents show promise but require further validation.
  • Supportive care remains the cornerstone of patient management.

Conclusions:

  • The development of effective COVID-19 therapies is ongoing.
  • Continued clinical trials are essential to establish proven treatment options.
  • A combination of supportive care and emerging therapies may be crucial for managing COVID-19.

More Related Videos

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.7K
A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects05:46

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects

Published on: May 4, 2021

5.6K

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
638
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
97
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
476
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
340
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
353